Edge Therapeutics
NJIT-EDC Biotechnology Incubator
139 South Street, Suite 102
New Providence
New Jersey
07974
United States
Tel: 800-208-EDGE
Fax: 800-208-3433
Website: http://www.edgetherapeutics.com/
Email: info@edgetherapeutics.com
61 articles about Edge Therapeutics
-
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Edge Therapeutics, Inc.
4/26/2018
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Edge Therapeutics, Inc. violated federal securities laws.
-
Shares of Edge Therapeutics were in free fall Wednesday afternoon following the company’s decision to discontinue development of a late stage treatment for adults with aneurysmal subarachnoid hemorrhage (aSAH).
-
Edge Therapeutics Reports Third Quarter 2017 Financial Results
11/1/2017
In addition, the company also appointed pharma vet Andrew Saik as CFO.
-
Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017
10/18/2017
The conference call will be available via phone and webcast.
-
Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, To Its Board Of Directors
9/19/2017
-
Edge Therapeutics Reports Second Quarter 2017 Financial Results And Continued Operational Progress
8/1/2017
-
Edge Therapeutics Announces Second Quarter Financial Results Conference Call On August 1, 2017
7/18/2017
-
Edge Therapeutics Receives Pediatric Investigation Plan Waiver From The EMA
6/8/2017
-
Edge Therapeutics Reports First Quarter 2017 Financial Results And Continued Operational Progress
5/3/2017
-
Edge Therapeutics Announces Conference Call On May 3, 2017 To Discuss First Quarter 2017 Financial Results
4/21/2017
-
Edge Therapeutics Announces $18 Million Registered Direct Offering Of Common Stock
4/19/2017
-
Edge Therapeutics Announces First Patient Randomized In Study Of Intracisternal Administration Of EG-1962 In Adults With Aneurysmal Subarachnoid Hemorrhage
3/13/2017
-
Edge Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
3/2/2017
-
Edge Therapeutics Announces Conference Call On March 2, 2017 To Discuss Fourth Quarter And Full Year 2016 Financial Results
2/23/2017
-
Edge Therapeutics Appoints Alyssa Wyant As Senior Vice President, Regulatory Affairs And Makes Inducement Grant Under NASDAQ Rule 5635(C)(4)
2/21/2017
-
Edge Therapeutics Announces Publication Of Phase I/II Data On EG-1962 For The Treatment Of Aneurysmal Subarachnoid Hemorrhage In Peer-Reviewed Medical Journal, Stroke
12/12/2016
-
Edge Therapeutics Reports Third Quarter Financial Results
11/1/2016
-
Edge Therapeutics To Host Conference Call On November 1, 2016 To Discuss Third Quarter Financial Results
10/25/2016
-
Edge Therapeutics Appoints Chief Operating Officer And Makes Inducement Grant Under NASDAQ Rule 5635(c)(4)
10/17/2016
-
Edge Therapeutics To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series And Participate In Additional Investor Conferences In September
9/8/2016